Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30413026 | 1.00 | NOTUM (0.53) | NOTUMKDM1AHDAC1HDAC6HDAC8 | |
| Hydrochloric Acid SCHEMBL25232027 | 0.99 | NOTUM (0.52) | NOTUMKDM1AHDAC1HDAC6HDAC8 | |
| SCHEMBL17807330 | 0.91 | NOTUM (0.64) | NOTUMKDM1AHDAC1HDAC6HDAC8 | |
| SCHEMBL28928097 | 0.91 | NOTUM (0.49) | NOTUMKDM1AHDAC1HDAC6HDAC8 | |
| SCHEMBL3363958 | 0.86 | NOTUM (0.50) | NOTUMKDM1AHDAC1HDAC6HDAC8 | |
| SCHEMBL14529913 | 0.86 | NOTUM (0.57) | NOTUMHDAC1HDAC6HDAC8ROCK2 | |
| SCHEMBL30898670 | 0.85 | NOTUM (0.53) | NOTUMKDM1AHDAC1HDAC6HDAC8 | |
| SCHEMBL13085702 | 0.85 | KDM1A (0.56) | NOTUMKDM1AHDAC1HDAC6HDAC8 | |
| SCHEMBL29384374 | 0.85 | KDM1A (0.56) | NOTUMKDM1AHDAC1HDAC6HDAC8 | |
| SCHEMBL25350959 | 0.85 | NOTUM (0.53) | NOTUMKDM1AHDAC1HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4192957-A2 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116113698-A | TRPML modulators | 卡斯玛治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2022032073-A2 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-2206714-B1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2014-11-27 | — | — | US | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
| WO-2008024497-A2 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024497-A2 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012622-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20070254904-A1 | Substituted Diaza-Spiro-[4.5]-Decane Derivatives and Their Use as Neurokinin Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254904-A1 | Substituted Diaza-Spiro-[4.5]-Decane Derivatives and Their Use as Neurokinin Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007057775-A1 | SPIROPIPERIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
| US-20070078152-A1 | Piperidine derivatives | AMGEN INC. | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | REN, AVPR2, RECQL | NOTUM 3318/4885KDM1A 2295/4885HDAC1 885/4885 |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | NOTUM 791/4885KDM1A 3628/4885HDAC1 608/4885 |
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD4, CD47 | NOTUM 2120/4885KDM1A 2618/4885HDAC1 500/4885 |
| US-20070078152-A1 | Piperidine derivatives | VIPR2, VIPR1, GRPR | NOTUM 1155/4885KDM1A 4260/4885HDAC1 651/4885 |
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | NOTUM 2050/4885KDM1A 3127/4885HDAC1 2067/4885 |
| US-20070254904-A1 | Substituted Diaza-Spiro-[4.5]-Decane Derivatives and Their Use as Neurokinin Antagonists | NPSR1, PROKR2, PROKR1 | NOTUM 2524/4885KDM1A 2966/4885HDAC1 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.